1. Home
  2. BRT vs CDXS Comparison

BRT vs CDXS Comparison

Compare BRT & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BRT Apartments Corp. (MD)

BRT

BRT Apartments Corp. (MD)

HOLD

Current Price

$14.93

Market Cap

269.9M

Sector

Real Estate

ML Signal

HOLD

Logo Codexis Inc.

CDXS

Codexis Inc.

HOLD

Current Price

$2.42

Market Cap

256.3M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRT
CDXS
Founded
1972
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Major Chemicals
Sector
Real Estate
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
269.9M
256.3M
IPO Year
1994
2008

Fundamental Metrics

Financial Performance
Metric
BRT
CDXS
Price
$14.93
$2.42
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$19.75
N/A
AVG Volume (30 Days)
21.5K
780.9K
Earning Date
05-08-2026
05-07-2026
Dividend Yield
7.03%
N/A
EPS Growth
N/A
43.82
EPS
N/A
N/A
Revenue
$97,028,000.00
$138,590,000.00
Revenue This Year
$3.82
$7.73
Revenue Next Year
$5.35
$14.24
P/E Ratio
N/A
N/A
Revenue Growth
1.46
32.30
52 Week Low
$13.18
$0.96
52 Week High
$16.69
$3.87

Technical Indicators

Market Signals
Indicator
BRT
CDXS
Relative Strength Index (RSI) 62.89 43.87
Support Level $14.23 $2.39
Resistance Level $14.93 $2.88
Average True Range (ATR) 0.33 0.15
MACD 0.04 -0.05
Stochastic Oscillator 76.34 12.17

Price Performance

Historical Comparison
BRT
CDXS

About BRT BRT Apartments Corp. (MD)

BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.

About CDXS Codexis Inc.

Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.

Share on Social Networks: